Home › Funds › Kynam Capital Management, LP › CADL

Kynam Capital Management, LP position in CADL

CANDEL THERAPEUTICS INC · Health Care

Kynam Capital Management, LP reported holding 96,741 shares of CADL (CANDEL THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$996K, representing 0.06% of its reported portfolio and ranking #30 among its reported holdings. Kynam Capital Management, LP has disclosed CADL holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)96.74K sh
Reported value held$996.43K
Portfolio Weight0.06%
First reportedQ1 2026
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Kynam Capital Management, LP's CADL position evolved

Kynam Capital Management, LP first disclosed a stake in CADL in Q1 2026 at 200,000 shares (US$980K). The position peaked in Q2 2026 at 96,741 shares, worth US$996K. Across 2 filings, Kynam Capital Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 96,741 shares valued at US$996K — a reduction of -103,259 shares quarter over quarter.. Notable position changes include a 52% trim in Q2 2026 (shares rose 1% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 200.00K $980.00K New
Q2 2026 96.74K $996.43K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CADL and 13F data

CADL (CANDEL THERAPEUTICS INC) is a Health Care company. 83 other funds we track also report a position in CADL — the largest reported positions include RTW INVESTMENTS, LP (US$66.1M), ACORN CAPITAL ADVISORS, LLC (US$36.0M), Portolan Capital Management, LLC (US$36.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CADL

All CADL fund holders →

FAQ

How long has Kynam Capital Management, LP held CADL?

Kynam Capital Management, LP has disclosed CADL holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Kynam Capital Management, LP's current position in CADL?

As of Q2 2026, Kynam Capital Management, LP holds 96.74K shares of CADL (CANDEL THERAPEUTICS INC), valued at $996.43K, representing 0.06% of its reported portfolio and ranking #30.

Has Kynam Capital Management, LP been buying or selling CADL?

In the latest 13F filing (Q2 2026), Kynam Capital Management, LP reduced its position in CADL. The position peaked in Q2 2026 at 96.74K shares.

Which other funds hold CADL?

Other major institutional holders of CADL include RTW INVESTMENTS, LP, ACORN CAPITAL ADVISORS, LLC, Portolan Capital Management, LLC, among 83 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.